› 6l9l

X-ray diffraction
2.4Å resolution

1D4 TCR recognition of H2-Ld a1a2 A5 Peptide Complexes

Released:
DOI: 10.2210/pdb6l9l/pdb
Model geometry
Fit model/data
PDB entry 6l9l coloured by chain, front view.
PDB entry 6l9l coloured by chain, side view.
PDB entry 6l9l coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
Wei P, Jordan KR, Buhrman JD, Lei J, Deng H, Marrack P, Dai S, Kappler JW, Slansky JE, Yin L
OpenAccess logo Proc Natl Acad Sci U S A 118 (2021)
PMID: 34074778

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
  • not assigned
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
hetero tetramer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-208738 (preferred)
Entry contents:
4 distinct polypeptide molecules
Macromolecules (4 distinct):
H-2 class I histocompatibility antigen, L-D alpha chain Chains: A, E
Molecule details ›
Chains: A, E
Length: 175 amino acids
Theoretical weight: 20.56 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P01897 (Residues: 25-199; Coverage: 52%)
Gene name: H2-L
Sequence domains: Class I Histocompatibility antigen, domains alpha 1 and 2
T Cell Receptor Chains: C, G
Molecule details ›
Chains: C, G
Length: 198 amino acids
Theoretical weight: 21.81 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
T Cell Receptor Chains: D, H
SER-PRO-SER-TYR-ALA-TYR-HIS-GLN-PHE Chains: B, F

Ligands and Environments

No bound ligands
No modified residues

Experiments and Validation Details

wwPDB Validation report is not available for this entry.
X-ray source: SSRF BEAMLINE BL19U1
Spacegroup: I4
Unit cell:
a: 148.044Å b: 148.044Å c: 169.449Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.204 0.203 0.234
Expression systems:
  • Escherichia coli
  • synthetic construct

Quick links

Citations

4 review citations

Nanomaterials: small particles show huge possibilities for cancer immunotherapy.
Chen et al. (2022)
3 more